In December, PersonGen won the " Excellent Project Award " in the 2021 National Disruptive Technology Innovation Competition.

In November, won the designation of " 2021 Hefei High-Growth Seed Enterprise ".

In November, PA3-17 injection was granted ODD by U.S. FDA.

In November, PersonGen.Anke Cellular Therapeutics Co., Ltd. won the " 2021 Hefei High-tech Zone Eagle Enterprise ".

In October, PersonGen won the " Annual Award of 2021 China Bioinnovative Drugs with the Most Growth Potential ".

In August, PersonGen announced the IND application of PA3-17 injection, a globally first autologous CD7-CAR-T cell product, was approved in China.

In June, Dr. Yang Lin was awarded the " Top 10 Drug Innovation Scientists of 2020 ".

In May, PersonGen has completed A Round of Financing led by bioVenture Capital, followed by Puen Guoxin Equity Investment and Sangel Capital.

In April, PersonGen invested and established PersonGen BioPharmaceutical (Shijiazhuang) Co., Ltd.

In March, PersonGen won " the Second Prize of Anhui Province Science and Technology Award ".

In March, after the completion of a major internal restructuring, PersonGen Anke became a wholly-owned subsidiary of PersonGen Group.